COMMUNIQUÉS West-GlobeNewswire

Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners
30/06/2026
Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing Intravacc offers four complementary vaccine [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
30/06/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
30/06/2026
ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma (“Orion”) and Shilpa Biologicals Private Limited [...]
Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe
30/06/2026
Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe Le Nexviazyme a atteint son objectif principal, à [...]
Le Centre National de Protonthérapie du Portugal sera équipé de deux solutions Proteus®ONE d’IBA
30/06/2026
Louvain-la-Neuve, Belgique, le 30 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026
Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
30/06/2026
The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED [...]
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
30/06/2026
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve [...]
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
30/06/2026
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune [...]
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
30/06/2026
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the [...]
Acorn Health Expands Autism Diagnostic Evaluations in Florida
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Acorn Health, a leading provider of Applied Behavior Analysis (ABA) therapy, has expanded autism diagnostic services in Florida. Comprehensive diagnostic evaluations [...]
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
29/06/2026
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical [...]
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
29/06/2026
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement- [...]
Publication relative à des notifications de transparence
29/06/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 29 juin 2026 , 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Lakefront Receives Transparency Notification from Madison Avenue Partners
29/06/2026
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian [...]
JellyFil Documents 2026 Supplement Facts Panel Composition, 8-Ingredient Proprietary Blend, and Manufacturing Disclosure for Its Gummy Dietary Supplement
29/06/2026
Once-daily men's gummy supplement featuring Maca, Ashwagandha, Tribulus, Arginine, Muira Puama, and Catuaba with 60-day money-back guarantee Largo, FL, June 29, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
29/06/2026
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in [...]
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
29/06/2026
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and [...]
DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossier
29/06/2026
Châtillon, France, le 29 juin (22 :00 CEST) 2026 DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans ; la Société travaille en collaboration avec [...]

Pages